NEW POSSIBILITIES IN THE TREATMENT OF CARDIOVASCULAR DISEASE USING COLCHICINE
https://doi.org/10.20514/2226-6704-2016-6-3-19-24
Abstract
The present review of the literature reflects issues of the colchicine’s pharmacological properties and mechanism of action. The authors provided the results of a number of scientific studies dedicated to the effects of colchicine on the cardiovascular pathology.
About the Authors
M. T. Vatutin
M. Gorky Donetsk National Medical University;
V.K. Gusak Institute of Urgent and Recovery Surgery
Ukraine
Ukraine
department of hospital therapy,
Donetsk
G. S. Smyrnova
M. Gorky Donetsk National Medical University;
V.K. Gusak Institute of Urgent and Recovery Surgery
Ukraine
Ukraine
department of hospital therapy,
Donetsk
E. O. Tselikova
M. Gorky Donetsk National Medical University
Ukraine
Ukraine
department of hospital therapy,
Donetsk
References
1. Nidorf S.M., Eikelboom J.W., Budgeon C.A., Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 2013; 61: 404-41.
2. Primatesta P., Plana E., Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011; 12: 103.
3. Gow P. Treating Gout in Patients With Comorbidities. Int. J. Clin. Rheumatol. 2011; 6: 625-633.
4. Deftereos S., Giannopoulos G., Papoutsidakis N. Colchicine and the Heart: Pushing the Envelope. J Am. Coll. Cardiol. 2013; 62(20): 1817-1825.
5. Chia E.W., Grainger R., Harper J.L. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br. J. Pharmacol. 2008; 153 (6): 1288-1295.
6. Alekberova Z.S., Barskova V.G. Colchicine in rheumatology: yesterday and today. Will there be tomorrow? Sovremennaya revmatologiya. 2010; 4 (2): 25-29. (In Russ.).
7. Marques-da-Silva C., Chaves M., Castro N. et al. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br. J. Pharmacol. 2011; 163 (5): 912-926.
8. Maidannyk V.G. Modern aspects of periodic fever with aphthous stomatitis, pharyngitis and cervical adenitis (Marshall's syndrome) in children. Mezhdunarodnyi zhurnal pediatrii, akusherstva i ginekologii. 2013; 3: 63-74. (In Russ.).
9. Cronstein B.N., Molad Y., Reibman J. et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J. Clin. Invest. 1995; 96 (2): 994-1002.
10. Dalbeth N., Lauterio T.J., Wolfe H.R. Mechanism of Action of Colchicine in the Treatment of Gout. Clin. Ther. 2014; 36 (10): 1465-1479.
11. Cotran R.S., Mayadas-Norton T. Endothelial adhesion molecules in health and disease. Pathol. Biol. (Paris). 1998; 46 (3): 164-70.
12. Misawa T., Takahama M., Kozaki T. et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol. 2013; 14: 454–460.
13. Wang Y, Viollet B, Terkeltaub R, Liu-Bryan R. AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. Ann Rheum Dis. 2014. [Epub ahead of print]. doi:10.1136/annrheumdis-2014-206074.
14. Preau S., Montaigne D., Modine T. et al. Macrophage migration inhibitory factor induces contractile and mitochondria dysfunction by altering cytoskeleton network in the human heart. Crit. Care Med. 2013; 41 (7): 125-33.
15. Menche D., Israel A., Karpatkin S. Platelets and Microtubules. Effect of colchicine and D2O on platelet aggregation and release induced by calcium ionophore A23187. J. Clin. Invest. 1980; 66 (2): 284–291.
16. Levy M., Eldor A., Zylber-Katz E., Ellakim M. The effect of long-term colchicine therapy in patients with recurrent polyserositis on the capacity of blood platelets to synthesize thromboxane A2. Br. J. Сlin. Pharmac. 1983;16:191-194.
17. Jung Y., Isaacs J.S., Lee S. et al. Microtubule Disruption Utilizes an NFB-dependent Pathway to Stabilize HIF-1 Protein. The journal of biological chemistry. 2003; 278 (9): 7445–7452.
18. Serebrovskaya TV. Gipoksiya+indutsibel'nyi faktor: rol' v patofiziologii dykhaniya (obzor). Ukraїns'kii pul'monologіchnii zhurnal. 2005; 3: 77-81. (In Russ.).
19. Shcherbak N.S., Galagudza M.M., Shlyakhto E.V. Rol' indutsiruemogo gipoksiei faktora-1 (HIF-1) v realizatsii tsitoprotektivnogo effekta ishemicheskogo i farmakologicheskogo postkonditsionirovaniya. Rossiiskii kardiologicheskii zhurnal. 2014; 11 (115): 70-75. (In Russ.).
20. Maisch B., Seferovic Р., Ristic A. et al. Guidelines on the diagnosis and management of pericardial diseases. Eur. Heart J. 2004; 25 (7): 587-610.
21. Imazio M., Bobbio M., Cecchi E. et al. Colchicine in Addition to Conventional Therapy for Acute Pericarditis. Results of the COlchicine for acute PEricarditis (COPE) Trial. Circulation. 2005; 112: 2012-2016.
22. Imazio M., Bobbio M., Cecchi E. et al. Colchicine as First-Choice Therapy for Recurrent Pericarditis. Results of the CORE (COlchicine for REcurrent pericarditis) Trial. Arch. Intern. Med. 2005; 165: 1987-1991.
23. Imazio M., Brucato A., Cemin R. et al. Colchicine for recurrent pericarditis (CORP): а randomized trial. Ann. Intern. Med. 2011; 155 (7): 409-414.
24. Imazio M., Trinchero R., Brucato A. et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur. Heart J. 2010; 31 (22): 2749-54.
25. Nidorf S.M., Eikelboom J.W., Budgeon C.A., Thompson P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 2013; 61: 404-410.
26. Frangogiannis N.G. Regulation of the Inflammatory Response in Cardiac Repair. Circ. Res. 2012; 110: 159-173.
27. Frangogiannis N.G. The inflammatory response in myocardial injury, repair, and remodeling. Nat. Rev. Cardiol. 2014; 11 (5): 255–265.
28. Folmes C.D., Clanachan A.S., Lopaschuk G.D. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr. Atheroscler. Rep. 2005; 7 (1): 63-70.
29. Parnes E.Y., Gavrilov S.A. O vozmozhnostyakh ispol'zovaniya lornoksikama u bol'nykh infarktom miokarda s pod"emom segmenta ST. Kardiologiya. 2011; 3: 23-28. (In Russ.).
30. Deftereos S., Giannopoulos G., Angelidis C. et al. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015; 132 (15): 1395-403.
31. Crittenden D.B,, Lehmann R.A., Schneck L. et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J. Rheumatol. 2012; 39 (7): 1458-64.
32. Raju N.C., Yi Q., Nidorf M. et al. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J. Thromb. Thrombolysis. 2012; 33: 88–94.
33. Uzun D. Assosiation system inflammation and post-implantation atrial fibrillation in eldery patients with implanted double chamber cardiac pacemaker. Sovremennaya meditsina: aktual'nye voprosy. 2015; 1 (37): 1-7. (In Russ.).
34. Deftereos S., Giannopoulos G., Kossyvakis C. et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J. Am. Coll. Cardiol. 2012; 60: 1790-1796.
35. Leong-Sit P., Roux J.F., Zado E. et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ. Arrhythm. Electrophysiol. 2011; 4 (1): 11-14.
36. Kamkin A., Kirischuk S., Kiseleva I. Single mechano-gated channels activated by mechanical deformation of acutely isolated cardiac fibroblasts from rats. Acta. Physiol. (Oxf). 2010; 199: 277-292
37. Kamkin A., Kiseleva I., Wagner K.D. et al. Mechanically induced potentials in rat atrial fibroblasts depend on actin and tubulin polymerisation. Pflugers. Arch. 2001; 442: 487-497.
38. Imazio M., Brucato A., Ferrazzi P. et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011; 124: 2290-2295.
39. Imazio M., Brucato A., Ferrazzi P. et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014; 312 (10): 1016-1023.
40. Jukema J.W., Verschuren J.J., Ahmed T.A., Quax P.H. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat. Rev. Cardiol. 2011; 9 (1): 53-62.
41. Katsaros K.M., Kastl S.P., Zorn G. Increased Restenosis Rate After Implantation of Drug-Eluting Stents in Patients With Elevated Serum Activity of Matrix Metalloproteinase-2 and -9. J. Am. Coll. Cardiol. Intv. 2010; 3 (1): 90-97.
42. O’Keefe J.H. Jr., McCallister B.D., Bateman T.M. Ineffectiveness of colchicine for the prevention of restenosis. J. Am. Coll. Cardiol. 1992; 19 (7): 1597-600.
43. Freed M., Safian R.D., O’Neill W.W. Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Am. J. Cardiol. 1995; 76: 1185-1188.
44. Deftereos S., Giannopoulos G., Raisakis K. et al. Colchicine treatment for prevention of bare-metal stent restenosis in diabetics. J. Am. Coll. Cardiol. 2013; 61: 1679-85.
45. Hofmann U., Frantz S. How can we cure a heart ‘in flame’? A translational view on inflammation in heart failure. Basic. Res. Cardiol. 2013; 108: 356.
46. Deftereos S., Giannopoulos G., Panagopoulou V. et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014; 2 (2): 131-137.
47. Van Tassell B., Canada J., Arena R., Abbate A. Colchicine in Stable Chronic Heart Failure. JCHF. 2014; 2 (5): 538.
Review
For citations:
Vatutin M.T., Smyrnova G.S., Tselikova E.O. NEW POSSIBILITIES IN THE TREATMENT OF CARDIOVASCULAR DISEASE USING COLCHICINE. The Russian Archives of Internal Medicine. 2016;6(3):19-24. (In Russ.) https://doi.org/10.20514/2226-6704-2016-6-3-19-24
Views:
1157
Email this article 